Status:
UNKNOWN
Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
Lead Sponsor:
West China Hospital
Conditions:
Stomach Neoplasms
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The incidence of adenocarcinomas of the esophagogastric junction (AEJ) has increased rapidly during the past decades. By the Siewert classification, the AEJ is the tumor center located 5 cm above the ...
Detailed Description
Standard Operating Procedure (SOP) 1. Preoperative evaluation Patients satisfied with inclusion/exclusion criteria will be informed to join in the clinical study and signature the inform consent. 2. ...
Eligibility Criteria
Inclusion
- Preoperative endoscopy and biopsy confirmed upper third gastric adenocarcinoma (Siewert-II/Siewert-III), and predictively feasible of radical total gastrectomy;
- Predictively resectable diseases, advanced gastric cancer, of preoperative staging JGCA 14th Edition cT2N0M0-T4aN3bM0, Ib-IIIc stage;
- Age：≤75 years, or ≥18 years;
- Without serious disease and malignance disease;
- WHO performance score ≤2, ASA score ≤3;
- No limit to sexual and race;
- Informed consent required.
Exclusion
- Patients with other severe complications cannot tolerate surgery: such as severe heart and lung diseases, heart function below clinical stage 2, uncontrollable hypertension, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc;
- Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation;
- Severity mental diseases;
- Primary lesion cannot be resected in the pattern of transabdominal proximal gastrectomy, but for total gastrectomy, Whipple's procedure, or combined organ resection or with a transthoracic approach surgery;
- After signature the Clinical trial agreement, patients and their agent will quit the trial.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT02313688
Start Date
January 1 2015
End Date
December 1 2023
Last Update
December 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041